Menu Search
Equities

Intellia Therapeutics Inc

38I:BRN

Intellia Therapeutics Inc

Actions
  • Price (CHF)24.63
  • Today's Change0.00 / 0.00%
  • Shares traded35.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

  • Revenue in USD (TTM)52.60m
  • Net income in USD-485.50m
  • Incorporated2014
  • Employees526.00
  • Location
    Intellia Therapeutics Inc40 Erie St Ste 130CAMBRIDGE 02139-4254United StatesUSA
  • Phone+1 (857) 285-6200
  • Fax+1 (302) 655-5049
  • Websitehttps://www.intelliatx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.